BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Surabgene lomparvovec readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Surabgene lomparvovec\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04704921-5173@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Surabgene lomparvovec: Phase 2/3 readout est. (NCT04704921)
DESCRIPTION:Surabgene lomparvovec\, phase 2/3\, Age-Related Macular Degener
 ation.\nStudy: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gen
 e Therapy Administered Via Subretinal Delivery One Time in Participants Wi
 th nAMD\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04704921
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06942520-5173@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Surabgene lomparvovec: Phase 2 readout est. (NCT06942520)
DESCRIPTION:Surabgene lomparvovec\, phase 2.\nStudy: Phase 2 Trial of RGX-3
 14 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)\nEst
 imated primary completion: December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06942520
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07592273-5173@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Surabgene lomparvovec: Phase 2/3 readout est. (NCT07592273)
DESCRIPTION:Surabgene lomparvovec\, phase 2/3.\nStudy: Surabgene Lomparvove
 c Administered in the Suprachoroidal Space in Adult Participants With Diab
 etic Retinopathy Without Center-Involved Diabetic Macular Edema\nEstimated
  primary completion: June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/surabgene-lomparvovec#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07592273
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03999801-5173@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Surabgene lomparvovec: Phase 2 readout est. (NCT03999801)
DESCRIPTION:Surabgene lomparvovec\, phase 2\, Age-Related Macular Degenerat
 ion.\nStudy: Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy\
 nEstimated primary completion: December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03999801
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007065-5173@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Surabgene lomparvovec: Phase 3 readout est. (NCT07007065)
DESCRIPTION:Surabgene lomparvovec\, phase 3\, Age-Related Macular Degenerat
 ion.\nStudy: Study to Assess the Injection Burden\, Adverse Events\, Chang
 e in Disease Activity\, and Long-Term Preservation of Visual Acuity of Sur
 abgene Lomparvovec in Adult Participants With Neovascular Age-Related Macu
 lar Degeneration (nAMD)\nEstimated primary completion: March 2033. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/surabgene-lomparvovec#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007065
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
